About chornixadm

This author has not yet filled in any details.
So far chornixadm has created 26 blog entries.

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix ASCO 2017: Dr Tomislav Dragovich

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

By | May 26th, 2017|Video|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

By | May 14th, 2017|Peer-reviewed medical publications|0 Comments

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments

Digital PCR of cfDNA for Transplant Rejetion

Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41

Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.

By | May 7th, 2017|Peer-reviewed medical publications|0 Comments

Using circulating cell-free DNA to monitor personalized cancer therapy

High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer

By | April 25th, 2017|Other publications|0 Comments

Chronix Biomedical is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the ASCO Annual Meeting.

Chronix Biomedical

The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.

By | April 24th, 2017|Chronix news|0 Comments

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

First study of a liquid biopsy to predict response to immunotherapy...

By | March 20th, 2017|Chronix news|0 Comments

Chronix Biomedical provides update on studies and presentations

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

By | February 27th, 2017|Chronix news|0 Comments

10 Cancer Symptoms

Chronix Biomedical

The best way to fight cancer is to diagnose it in its early stage...

By | February 6th, 2017|Chronix news|0 Comments